DLL4: A Key Target for Angiogenesis Regulation

Recently, Co.unlink Medicines and Compass Therapeutics announced that the phase II/III clinical trials of the VEGF/DLL4 bispecific antibody tovecimig (CTX-009/ES104) for second-line cholangiocarcinoma treatment have reached the primary endpoints. The tovecimig-based combination regimen is expected to become a new standard for second-line cholangiocarcinoma treatment globally, bringing new hope to patients.

Delta-like ligand 4 (DLL4), a key ligand in the Notch signaling pathway, plays a central role in angiogenesis and vascular remodeling. Aberrant expression of DLL4 is closely linked to abnormal angiogenesis in various pathological conditions, such as tumors, retinopathies, and cardiovascular diseases. Research indicates that DLL4 is not only a critical regulator of angiogenesis but also may contribute to disease progression by influencing endothelial cell behavior, making it a hot spot in disease therapy research in recent years.

1. DLL4 Mechanisms and Signaling Pathways

2. Related Diseases

3. Drug Research Advances

4. DLL4-Related Products Recommendation

1. DLL4 Mechanisms and Signaling Pathways

1.1 Regulation of Angiogenesis by DLL4-Notch Signaling

DLL4 inhibits excessive sprouting of endothelial cells by activating Notch signaling, maintaining vascular branch balance. Under physiological conditions, DLL4 is predominantly highly expressed in tip cells of vascular endothelial cells. Through paracrine action, it binds to Notch receptors on adjacent cells, suppressing their tip cell characteristics and promoting stalk cell differentiation. This maintains vascular branch balance and prevents excessive vascular branching ^[2]. However, under pathological conditions, such as in the tumor microenvironment, DLL4 expression is upregulated. On one hand, by activating the Notch signaling pathway, DLL4 can inhibit angiogenesis. On the other hand, abnormal activation of this signaling may lead to aberrant vascular structures, thereby promoting tumor progression ^[1].

1.2 Interactions with Other Signaling Pathways

VEGF Pathway: VEGF can induce DLL4 expression, forming a negative feedback loop. When DLL4 is inhibited, excessive VEGF-driven angiogenesis occurs, indicating that DLL4 and VEGF work synergistically to regulate angiogenesis. ^[1]
YAP-DLL4-Notch Axis: Under hypoxic conditions, AFAP1L1 is activated via HIF-1α, which inhibits YAP phosphorylation, promotes DLL4 expression, and activates Notch signaling. This regulates tip cell behavior of endothelial cells and affects angiogenesis and vascular remodeling ^[8].
KLF13-DLL4-Notch2 Axis: In a muscle atrophy model, KLF13 alleviates atrophy by inhibiting the DLL4-Notch2 signaling pathway. This reveals DLL4's novel role in muscle metabolism and vascular interaction, suggesting its impact on organismal metabolism through interactions with other tissues ^[9].

1.3 Intracellular Regulatory Mechanisms

DLL4 expression is regulated by multiple transcription factors and epigenetic mechanisms. For example, in diabetic models, glucocorticoids downregulate KLF13 by inhibiting MYOD1-mediated transcriptional activation, indirectly promoting DLL4 expression. Additionally, the ubiquitination pathway, such as FBXW7-mediated degradation, regulates DLL4 protein levels, affecting its intracellular stability and function ^[9].

2. Related Diseases

2.1 Tumors

Tumor Angiogenesis Promotion: DLL4 is highly expressed in various tumors, such as colorectal cancer, lung cancer, and liver cancer. By activating the Notch signaling pathway, DLL4 inhibits normal angiogenesis, forming aberrant vascular networks that facilitate tumor growth and metastasis. For instance, in colorectal cancer, elevated DLL4 correlates with increased tumor microvascular density and poor prognosis ^[11,12]. Preclinical studies show that anti-DLL4 antibodies can inhibit abnormal vascular branching in mouse models. However, long-term DLL4 inhibition may induce vascular sarcomas and other toxicities ^[1].
Drug Resistance: In bevacizumab-treated colorectal cancer patients, elevated DLL4 expression is associated with drug resistance, indicating DLL4 as a potential biomarker for anti-angiogenic therapy resistance ^[11,12].
Immune Evasion: DLL4 promotes immune evasion by regulating the polarization of tumor-associated macrophages, fostering an immunosuppressive microenvironment.

2.2 Retinopathies

Retinopathy of Prematurity (ROP): In hypoxia-induced retinopathy models, DLL4 deficiency leads to excessive angiogenesis. Activating Notch signaling reduces abnormal neovascularization, highlighting DLL4's critical role in retinal angiogenesis regulation and its association with ROP ^[5,8].
Diabetic Retinopathy (DR): Hyperglycemia upregulates DLL4 in endothelial cells via HIF-1α, promoting abnormal angiogenesis and vascular leakage. Inhibiting DLL4 activity may alleviate retinal edema and improve vascular barrier function ^[5,8].
Age-Related Macular Degeneration (AMD): DLL4 is highly expressed in choroidal neovascularization of wet AMD patients. By activating Notch signaling, it promotes abnormal endothelial cell migration and lumen formation ^[5].

2.3 Cardiovascular Diseases

Atherosclerosis: Palmitic acid activates DLL4-Notch signaling in macrophages, increasing inflammatory factor secretion and exacerbating plaque instability and endothelial injury ^[13].
Vascular Remodeling: In vascular injury models, DLL4 regulates smooth muscle cell phenotype switching, promoting vascular stenosis and neointima formation ^[4].
Myocardial Ischemia/Reperfusion Injury: DLL4 deficiency may reduce endothelial cell apoptosis post-ischemia and improve cardiac function, indicating DLL4's dual regulatory role in ischemic heart disease ^[5].

2.4 Chronic Kidney Disease

Uremic toxin indoxyl sulfate activates the OATP2B1-DLL4 axis in renal tubular epithelial cells, inducing macrophage pro-inflammatory polarization and aggravating renal interstitial fibrosis and dysfunction.

2.5 Muscle Atrophy and Metabolic Diseases

In diabetic and glucocorticoid-induced muscle atrophy models, KLF13 deficiency causes excessive DLL4-Notch2 signaling, inhibiting myocyte differentiation and promoting muscle protein degradation. Activating KLF13 or inhibiting DLL4 improves muscle quality and function ^[9].

2.6 Hereditary Vascular Diseases

DLL4 gene mutations cause hereditary capillary malformations, characterized by abnormal skin and mucosal vascular proliferation, highlighting DLL4's role in maintaining vascular homeostasis ^[6].

3. Drug Research Advances

DLL4 is a key Notch signaling ligand regulating angiogenesis and vascular maturation. Anti-DLL4 antibodies can suppress tumor angiogenesis but may induce toxicities like hepatic vascular sarcomas with long-term use. Combining anti-DLL4 antibodies with anti-VEGF drugs enhances antitumor effects in mouse models and reduces abnormal vascular perfusion and drug resistance risks. Two DLL4 × VEGF bispecific antibody pipelines are currently under research, with the highest stage at phase II/III. Below is a table of ongoing pipelines:

Drug	Mechanism of Action	Drug Type	Indications	Developers	Development Stage
Tovecimig	DLL4 inhibitor and VEGF-A inhibitor	Bispecific antibody	gallbladder cancer, intrahepatic cholangiocarcinoma, cholangiocarcinoma, colorectal cancer, metastatic colorectal cancer, rectal cancer, ovarian cancer	Compass Therapeutics LLC, et al.	Phase II/III
Navicixizumab	DLL4 inhibitor and VEGF inhibitor	Bispecific antibody	Advanced malignant solid tumors, colorectal cancer, ovarian cancer, gastric cancer, triple-negative breast cancer, etc.	Oncxerna Therapeutics, Inc., et al.	Phase II
Anti-DLL4 antibody (Regeneron)	DLL4 inhibitor	Antibody	Graft-versus-host disease	Regeneron Pharmaceuticals, Inc.	Preclinical

4. DLL4-Related Products Recommendation

CUSABIO provides high-activity DLL4 recombinant proteins, antibodies, and ELISA kits to support researchers in studying DLL4 mechanisms and exploring its clinical potential.

● DLL4 Recombinant Proteins

Recombinant Human Delta-like protein 4 (DLL4),partial (Active) CSB-MP878862HU

● DLL4 Antibodies

DLL4 (Navicixizumab) Recombinant Monoclonal Antibody

CSB-RA878862MA1HU

Applications: ELISA

DLL4 Antibody

CSB-PA006949LA01HU

Applications: ELISA, IF

● DLL4 ELISA Kits

Human Delta-like protein 4(DLL4) ELISA kit

CSB-EL006949HU

References

[1] Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7283):E6-E7. DOI: 10.1038/nature08751.

[2] Pitulescu ME, Schmidt I, Giaimo BD, et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat Cell Biol. 2017;19(8):915-927. DOI: 10.1038/ncb3555.

[3] Folkman J. Angiogenesis: an organizing principle for drug discovery. Nat Rev Drug Discov. 2007;6(4):273-286. DOI: 10.1038/nrd2273.

[4] Bassel-Duby R, Olson EN. Notch signaling in skeletal muscle development and disease. Cold Spring Harb Perspect Biol. 2015;7(10):a019067. DOI: 10.1101/cshperspect.a019067.

[5] Yang JM, Park CS, Kim SH, et al. Dll4 Suppresses Transcytosis for Arterial Blood-Retinal Barrier Homeostasis. Circ Res. 2020;126(6):767-783. DOI: 10.1161/CIRCRESAHA.119.316476.

[6] National Cancer Institute. DLL4 wt Allele. NCI Thesaurus. Published February 8, 2020. DOI: 10.32388/QULVH4.

[7] Hellström M, Phng LK, Hofmann JJ, et al. Dll4 signaling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776-780. DOI: 10.1038/nature05571.

[8] Ren JS, Bai W, Ding JJ, et al. Hypoxia-induced AFAP1L1 regulates pathological neovascularization via the YAP-DLL4-NOTCH axis. J Transl Med. 2023;21(1):651. DOI: 10.1186/s12967-023-04503-x.

[9] Yang S, Xiong LJ, Yang GY, et al. KLF13 restrains Dll4-muscular Notch2 axis to improve muscle atrophy. J Cachexia Sarcopenia Muscle. 2024;15(5):1869-1882. DOI: 10.1002/jcsm.13538.

[10] Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumor growth by promoting nonproductive angiogenesis. Nature. 2006;444(7121):1032-1037. DOI: 10.1038/nature05329.

[11] Jacobsen KS, Holm T, Knoop C, et al. Notch and DLL4 expression in bevacizumab-treated colon cancer patients. Br J Cancer. 2012;107(12):1987-1993. DOI: 10.1038/bjc.2012.628.

[12] Jacobsen KS, Holm T, Knoop C, et al. Notch and DLL4 expression in bevacizumab-treated colon cancer patients [erratum]. Br J Cancer. 2013;108(3):670. DOI: 10.1038/bjc.2012.736.

[13] Li Y, Zhang Y, Wang X, et al. Palmitic acid in type 2 diabetes mellitus promotes atherosclerotic plaque vulnerability via macrophage Dll4 signaling. Atherosclerosis. 2021;327:134-144. DOI: 10.1016/j.atherosclerosis.2021.09.014.

Cite this article

CUSABIO team. DLL4: A Key Target for Angiogenesis Regulation. https://www.cusabio.com/c-21229.html

Comments